User profiles for P. Bossi

Paolo Bossi

Associate Professor of Medical Oncology, University of Brescia
Verified email at unibs.it
Cited by 12829

[HTML][HTML] The spectrum of malnutrition/cachexia/sarcopenia in oncology according to different cancer types and settings: a narrative review

P Bossi, P Delrio, A Mascheroni, M Zanetti - Nutrients, 2021 - mdpi.com
Nutritional status in oncological patients may differ according to several modifiable and non-modifiable
factors. Knowledge of the epidemiology of malnutrition/cachexia/sarcopenia may …

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

…, A Ariyawardana, ME Correa, V Ranna, P Bossi… - Cancer, 2020 - Wiley Online Library
Background Mucositis is a significant toxicity of cancer therapy with numerous systemic
sequelae. The goal of this systematic review was to update the Multinational Association of …

[HTML][HTML] Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives

…, P Bossi, A Dasari, L Fallowfield, P Gascón… - Supportive care in …, 2020 - Springer
Background Digital health provides solutions that capture patient-reported outcomes (PROs)
and allows symptom monitoring and patient management. Digital therapeutics is the …

Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines

Y Zadik, PR Arany, ER Fregnani, P Bossi… - Supportive Care in …, 2019 - Springer
Purpose To systematically review the literature and update the evidence-based clinical
practice guidelines for the use of photobiomodulation (PBM), such as laser and other light …

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study

LD Locati, P Bossi, F Perrone, P Potepan, F Crippa… - Oral oncology, 2009 - Elsevier
EGFR overexpression in salivary gland carcinomas provides the rational for the
investigation of anti-EGFR treatments in recurrent and/or metastatic salivary gland cancers (RMSGCs). …

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

P Bossi, AT Chan, L Licitra, A Trama… - Annals of …, 2021 - annalsofoncology.org
Nasopharyngeal carcinoma (NPC) is a disease with unique epidemiological features. The
distribution of the disease demonstrates a clear regional, racial and gender prevalence. In …

[HTML][HTML] Global cancer control: responding to the growing burden, rising costs and inequalities in access

…, JS Frenel, M Karamouzis, M Strijbos, O Yazici, P Bossi… - ESMO open, 2018 - Elsevier
The cancer burden is rising globally, exerting significant strain on populations and health
systems at all income levels. In May 2017, world governments made a commitment to further …

Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations

P Bossi, G Viale, AKC Lee, RM Alfano, G Coggi… - Cancer research, 1995 - AACR
Angiogenesis is a crucial step in tumor growth and progression. Its quantitation by
microvessel counting is of prognostic value in several types of malignancies. Scarce data are …

[HTML][HTML] Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients

…, JB Epstein, S Elad, J Allemano, P Bossi… - Supportive Care in …, 2013 - Springer
Purpose The aim of this project was to develop clinical practice guidelines on the use of
antimicrobials, mucosal coating agents, anesthetics, and analgesics for the prevention and …

[HTML][HTML] Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis

…, S Raimondi, S Chiocca, C Miccolo, P Bossi… - PLoS …, 2022 - journals.plos.org
… All reported p values were two sided and p<0.05 was considered statistically significant. …
regular doses and those involving high doses (p = 0.18; p = 0.28, respectively for the ones with …